OVERVIEW OF OXBRYTA LAWSUIT
Lawsuits are being filed against Pfizer by individuals who suffered severe side effects and injuries after using Oxbryta (Voxelotor).
A Closer Look at Lawsuit
Lawsuits are being filed against Pfizer by individuals who suffered severe side effects and injuries after using Oxbryta (Voxelotor). The allegations claim that the drug manufacturer did not adequately inform sickle cell anemia patients about the potential dangers of the medication. Instead of aiding in the management of anemia related to sickle cell disease (SCD), many users experienced serious side effects, including:
– Increased vaso-occlusive crises (VOC)
– Stroke
– Organ failure (such as kidney failure)
– Arthritis
– Death
Effect
These adverse effects were identified in two registry-based studies conducted in the U.S. following clinical trials and by the European Medicines Agency (EMA). As a result of these serious side effects, Pfizer announced an international, voluntary recall of Oxbryta on September 25, 2024. The following day, the U.S. FDA released a warning regarding Oxbryta aimed at patients, caregivers, and healthcare professionals. This notice instructed doctors to cease prescribing Oxbryta immediately and urged patients to consult their healthcare providers about discontinuing the drug.
Currently, Pfizer’s patient information label for Oxbryta does not alert physicians or patients to the risks of VOCs, stroke, organ failure, or heightened risk of death. The warning label was updated in August 2023, but these severe side effects were not included. Patients who have suffered from these side effects are taking legal action against Pfizer for failing to adequately warn them about the risks associated with Oxbryta. These side effects have had significant repercussions for patients and their families, and attorneys are working to secure compensation for those harmed by Oxbryta and their surviving relatives.
FIND OUT IF YOU QUALIFY TODAY!
